Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJeph Herrin, PhD
Assistant Professor of Medicine (Cardiology), Internal MedicineAbout
Research
Publications
Featured Publications
Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018
Caraballo C, Ndumele CD, Roy B, Lu Y, Riley C, Herrin J, Krumholz HM. Trends in Racial and Ethnic Disparities in Barriers to Timely Medical Care Among Adults in the US, 1999 to 2018. JAMA Health Forum 2022, 3: e223856. PMID: 36306118, PMCID: PMC9617175, DOI: 10.1001/jamahealthforum.2022.3856.Peer-Reviewed Original ResearchConceptsTimely medical careSerial cross-sectional studyNational Health Interview SurveyCross-sectional studyHealth Interview SurveyMedical careLack of transportationEthnic disparitiesHispanics/LatinosWhite individualsEthnicity groupsInterview SurveyCost of careSelf-reported raceStudy cohortClinic hoursMAIN OUTCOMEMedical officesCarePrevalenceLatino individualsBlack individualsSignificant differencesSignificant increasePopulation groupsIdentifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA
Herrin J, Yu H, Venkatesh AK, Desai SM, Thiel CL, Lin Z, Bernheim SM, Horwitz LI. Identifying high-value care for Medicare beneficiaries: a cross-sectional study of acute care hospitals in the USA. BMJ Open 2022, 12: e053629. PMID: 35361641, PMCID: PMC8971780, DOI: 10.1136/bmjopen-2021-053629.Peer-Reviewed Original ResearchConceptsAcute care hospitalsHigh-value careStar hospitalsCare hospitalMedicare spendingEligible Medicare patientsRetrospective observational studyCross-sectional studyNon-teaching statusHigh-quality careHigh-quality hospitalsLow-cost hospitalsHigh-cost hospitalsCharacteristics of hospitalsValue of careSecondary outcomesPrimary outcomeMedicare patientsObservational studyMedicare beneficiariesHospitalQuality careOverall star ratingHospital ValueComparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment
Herrin J, Abraham NS, Yao X, Noseworthy PA, Inselman J, Shah ND, Ngufor C. Comparative Effectiveness of Machine Learning Approaches for Predicting Gastrointestinal Bleeds in Patients Receiving Antithrombotic Treatment. JAMA Network Open 2021, 4: e2110703. PMID: 34019087, PMCID: PMC8140376, DOI: 10.1001/jamanetworkopen.2021.10703.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnticoagulantsAntifibrinolytic AgentsAtrial FibrillationClinical Decision-MakingCohort StudiesCross-Sectional StudiesFemaleFibrinolytic AgentsGastrointestinal HemorrhageHumansMachine LearningMaleMiddle AgedMyocardial IschemiaPredictive Value of TestsRetrospective StudiesRisk AssessmentThienopyridinesUnited StatesVenous ThromboembolismYoung AdultConceptsGastrointestinal bleedingIschemic heart diseaseCross-sectional studyThienopyridine antiplatelet agentAntithrombotic treatmentVenous thromboembolismAntiplatelet agentsRandom survival forestStudy cohortAtrial fibrillationValidation cohortHeart diseaseHAS-BLED risk scoreRetrospective cross-sectional studyCox proportional hazards regressionHAS-BLED scorePrior GI bleedPatients 18 yearsCohort of patientsEntire study cohortProportional hazards regressionOptumLabs Data WarehouseMedicare Advantage enrolleesPositive predictive valueRisk prediction modelPopulation well-being and electoral shifts
Herrin J, Witters D, Roy B, Riley C, Liu D, Krumholz HM. Population well-being and electoral shifts. PLOS ONE 2018, 13: e0193401. PMID: 29529049, PMCID: PMC5846778, DOI: 10.1371/journal.pone.0193401.Peer-Reviewed Original Research
2025
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial
Sklepinski S, Deng Y, Swarna K, Herrin J, Polley E, Neumiller J, Galindo R, Umpierrez G, Ross J, Borah B, Maron B, Mickelsonb M, McCoy R. Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Research And Clinical Practice 2025, 229: 112910. PMID: 40983112, DOI: 10.1016/j.diabres.2025.112910.Peer-Reviewed Original ResearchAssociated with lower riskModerate cardiovascular riskAll-Cause MortalityClaims dataCardiovascular riskLower risk of MACECardiovascular outcomesRisk of MACEData of adultsInverse probabilityTarget trialsInverse probability of treatmentCardiovascular risk reductionProbability of treatmentType 2 diabetes mellitusType 2 diabetesReceptor agonistsEffects of GLP-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsRisk reductionMajor adverse cardiovascular eventsComposite major adverse cardiovascular eventsRandomized treatment assignmentComparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk
Kalathiya U, Herrin J, Swarna K, Deng Y, Polley E, Neumiller J, Galindo R, Umpierrez G, Ross J, Mickelson M, McCoy R. Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk. Endocrine Practice 2025 PMID: 40945659, DOI: 10.1016/j.eprac.2025.09.004.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsRisk of acute pancreatitisAssociated with lower riskGLP-1RAAcute pancreatitisPancreatic cancerType 2 diabetesPancreatitis eventsReceptor agonistsDipeptidyl peptidase-4 inhibitor therapyGlucagon-like peptide-1 receptor agonistsRisk of pancreatic cancerLow riskFee-for-service MedicarePeptide-1 receptor agonistsGLP-1 receptor agonistsIncident acute pancreatitisModerate cardiovascular disease riskDe-identified claims dataComparative riskAcute pancreatitis riskAssociated with higher riskInverse probabilityPeptidase-4 inhibitorsCharacterization of Postural Orthostatic Tachycardia Syndrome in Long COVID Self-reported Data From the LISTEN Study
AL Mouslmani M, Sawano M, Arun A, Wu Y, Shah R, Kaleem S, Zhou T, Murugiah K, Lu Y, Herrin J, Bishop P, Taub P, Peixoto A, Bhattacharjee B, Iwasaki A, Krumholz H. Characterization of Postural Orthostatic Tachycardia Syndrome in Long COVID Self-reported Data From the LISTEN Study. JACC Advances 2025, 4: 101873. PMID: 40883051, PMCID: PMC12399260, DOI: 10.1016/j.jacadv.2025.101873.Peer-Reviewed Original ResearchSelf-reported diagnosisPostural orthostatic tachycardia syndromeHealth statusSelf-reported long COVIDOrthostatic tachycardia syndromeHealth status of peopleEuroQol visual analog scaleDiagnosis of postural orthostatic tachycardia syndromeOnline observational studyExperiences of peopleStatus of peoplePostacute COVID-19 syndromeChest painVisual analog scaleHigher RatesExcessive fatigueHealth burdenMyalgic encephalomyelitis/chronic fatigue syndromeSocial isolationInternal tremorExercise intoleranceObservational studyFinancial difficultiesAnalog scaleSuicidal thoughtsEvaluating Blood Pressure Response Patterns to Exercise Stress Testing
Nene A, Lee D, Agboola O, Herrin J, Onuma O, Feher A, Miller E, Lu Y, Meadows J, Spatz E. Evaluating Blood Pressure Response Patterns to Exercise Stress Testing. Hypertension 2025, 82: 1663-1674. PMID: 40859827, DOI: 10.1161/hypertensionaha.124.23717.Peer-Reviewed Original ResearchConceptsHypertensive response to exerciseBlood pressureComposite outcomeResponse to exerciseCardiovascular eventsBlood pressure trajectoriesClass IIComposite outcome of myocardial infarctionBlood pressure response patternsAssociated with future cardiovascular eventsPeak blood pressureAssociated with cardiovascular outcomesOutcome of myocardial infarctionPressure trajectoriesExercise stress testDiastolic blood pressureSystolic blood pressureExercise tolerance testClass II and IIITrajectories of blood pressureSystolic blood pressure trajectoriesStages 1 to 3Heart failureCardiovascular outcomesTolerance testRisk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide
Barkmeier A, Deng Y, Swarna K, Herrin J, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmology Retina 2025 PMID: 40774571, DOI: 10.1016/j.oret.2025.07.019.Peer-Reviewed Original ResearchDiabetic macular edemaProliferative diabetic retinopathyComparison of patientsDiabetic retinopathyGLP-1Type 2 diabetesRisk of sight-threatening diabetic retinopathyTreatment of diabetic macular edemaGLP-1 RA treatmentSight-threatening diabetic retinopathyGlucagon-like peptide-1 receptor agonistsScore-weighted Cox proportional hazards modelGLP-1 RA usePeptide-1 receptor agonistsModerate cardiovascular disease riskAdvanced diabetic retinopathyPropensity score-weighted Cox proportional hazards modelsDiabetic retinopathy complicationsEffect of semaglutideGLP-1 RAsRetrospective observational studyCox proportional hazards modelsModerate cardiovascular riskMedicare fee-for-service planRoutine clinical practiceFill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021
Steiger K, Swarna K, Herrin J, McCoy R. Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021. Journal Of General Internal Medicine 2025, 1-8. PMID: 40760383, DOI: 10.1007/s11606-025-09784-0.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsType 2 diabetesBackgroundGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsCotransporter-2 inhibitorsFilling patternGlucose-lowering drugsAssociated with lower oddsAssociated with greater oddsCardiorenal comorbiditiesKidney benefitsReceptor agonistsKidney outcomesSodium-glucoseResultsThe studyHigher oddsLower oddsGreater oddsOlder ageOddsORGLP1RACKDASCVDKidney
News
News
- April 17, 2025
Lower Blood Pressure May Offer Benefits Even for the Very Elderly
- July 02, 2024
Yale Faculty Members Named to JACC Editorial Board
- April 03, 2024
Assessing Equity Measures in Hospital Readmissions
- April 01, 2024
Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions
Get In Touch
Contacts
Email